PMID- 31759433
OWN - NLM
STAT- MEDLINE
DCOM- 20200427
LR  - 20200427
IS  - 1937-6448 (Print)
IS  - 1937-6448 (Linking)
VI  - 349
DP  - 2019
TI  - Ex vivo dendritic cell generation-A critical comparison of current approaches.
PG  - 251-307
LID - S1937-6448(19)30100-5 [pii]
LID - 10.1016/bs.ircmb.2019.10.003 [doi]
AB  - Dendritic cells (DCs) are professional antigen-presenting cells, required for the 
      initiation of naive and memory T cell responses and regulation of adaptive 
      immunity. The discovery of DCs in 1973, which culminated in the Nobel Prize in 
      Physiology or Medicine in 2011 for Ralph Steinman and colleagues, initially 
      focused on the identification of adherent mononuclear cell fractions with 
      uniquely stellate dendritic morphology, followed by key discoveries of their 
      critical immunologic role in initiating and maintaining antigen-specific immunity 
      and tolerance. The medical promise of marshaling these key capabilities of DCs 
      for therapeutic modulation of antigen-specific immune responses has guided 
      decades of research in hopes to achieve genuine physiologic partnership with the 
      immune system. The potential uses of DCs in immunotherapeutic applications 
      include cancer, infectious diseases, and autoimmune disorders; thus, methods for 
      rapid and reliable large-scale production of DCs have been of great academic and 
      clinical interest. However, difficulties in obtaining DCs from lymphoid and 
      peripheral tissues, low numbers and poor survival in culture, have led to 
      advancements in ex vivo production of DCs, both for probing molecular details of 
      DC function as well as for experimenting with their clinical utility. Here, we 
      review the development of a diverse array of DC production methodologies, ranging 
      from cytokine-based strategies to genetic engineering tools devised for enhancing 
      DC-specific immunologic functions. Further, we explore the current state of DC 
      therapies in clinic, as well as emerging insights into physiologic production of 
      DCs inspired by existing therapies.
CI  - (c) 2019 Elsevier Inc. All rights reserved.
FAU - Han, Patrick
AU  - Han P
AD  - Department of Chemical and Environmental Engineering, School of Engineering and 
      Applied Science, Yale University, New Haven, CT, United States.
FAU - Hanlon, Douglas
AU  - Hanlon D
AD  - Department of Dermatology, School of Medicine, Yale University, New Haven, CT, 
      United States.
FAU - Sobolev, Olga
AU  - Sobolev O
AD  - Department of Dermatology, School of Medicine, Yale University, New Haven, CT, 
      United States.
FAU - Chaudhury, Rabib
AU  - Chaudhury R
AD  - Department of Chemical and Environmental Engineering, School of Engineering and 
      Applied Science, Yale University, New Haven, CT, United States.
FAU - Edelson, Richard L
AU  - Edelson RL
AD  - Department of Dermatology, School of Medicine, Yale University, New Haven, CT, 
      United States. Electronic address: redelson@yale.edu.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20191115
PL  - Netherlands
TA  - Int Rev Cell Mol Biol
JT  - International review of cell and molecular biology
JID - 101475846
RN  - 0 (Vaccines)
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Dendritic Cells/*cytology/*immunology
MH  - Genetic Engineering
MH  - Humans
MH  - Immunotherapy
MH  - Inflammation/immunology
MH  - Vaccines/immunology
OTO - NOTNLM
OT  - Clinical trials
OT  - Cytokine
OT  - Dendritic cell
OT  - Ex vivo production
OT  - Extracorporeal photopheresis
OT  - Genetic engineering
OT  - Immunotherapy
OT  - Physiologic generation
EDAT- 2019/11/25 06:00
MHDA- 2020/04/28 06:00
CRDT- 2019/11/25 06:00
PHST- 2019/11/25 06:00 [entrez]
PHST- 2019/11/25 06:00 [pubmed]
PHST- 2020/04/28 06:00 [medline]
AID - S1937-6448(19)30100-5 [pii]
AID - 10.1016/bs.ircmb.2019.10.003 [doi]
PST - ppublish
SO  - Int Rev Cell Mol Biol. 2019;349:251-307. doi: 10.1016/bs.ircmb.2019.10.003. Epub 
      2019 Nov 15.